Pfizer (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) have signeda letter of intent with Brazil-based Eurofarma Laboratórios SA, to manufacture its mRNACOVID-19 vaccine, COMIRNATY for distribution within Latin America.
Eurofarma will obtain drug product drug product from the U.S., and will perform manufacturing activities, with distribution expected to start in 2022.
Pfizer-BioNTech's COVID-19 vaccine supply chain and manufacturing network will now span four continents and include more than 20 manufacturing facilities.
At full operational capacity, the annual production is expected to exceed 100M finished doses annually. All doses will exclusively be distributed within Latin America.
To date, Pfizer and BioNTech have shipped more than 1.3B COVID-19 vaccine doses to more than 120 countries and territories.
Recently, Pfizer/BioNTech started rolling submission for FDA approval of booster COVID-19 shot.
精彩评论